Eli Lilly) should use a non-oral form of contraception, which is a barrier method, such as a condom or a non-oral contraceptive, such as the coil or implant, for four weeks after starting GLP-1 medicines and for four weeks after any increase in dose
Van Gaal LF, Mertens IL, De Block CE
Early podocyte injury, characterized by their effacement and detachment, compromises the filtration barrier integrity and contributes to albuminuria and subsequent glomerulosclerosis [1,19]
More significantly, in Gileads efforts to further convenience and reduce treatment duration (and remain competitive), Harvoni was approved in the U.S., Canada, the EU and Switzerland in 2014, and debuted at $2.1 billion in sales for the year (and a whopping $3.6 billion in 1Q15)